Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
October 17, 2019
Nanologica

Nanologica's collaboration project continued

Peter Hartman spoke to Rapidus about investment promotion and the new joint microbiome project with Copenhagen Capacity and Invbest in Skåne.

Nanologica's collaboration project continued

-
Nanologica
-
October 17, 2019

The agreement between Nanologica and AstraZeneca for the evaluation of Nanologica’s pending patented technology applied to AstraZeneca materials has been extended.

The evaluation of the NLAB Silica™ drug delivery platform started at the beginning of 2019. It has now been decided to prolong and expand this collaboration project. The extension of the project is regulated under the same feasibility agreement as signed in January 2019. This extension will further evaluate Nanologica’s platform for the purpose of improving the formulation of an API.

” We are very positive about the extension of the project and are happy to keep working together with AstraZeneca”, says Nanologica’s CEO Andreas Bhagwani.

For further information, please contact:

Andreas Bhagwani, CEO of Nanologica
phone: +46 70 316 17 02 or e-mail: andreas.bhagwani@nanologica.com

About Nanologica AB (publ)
Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size and type of porosity of silica particles. This knowledge is applied within drug delivery and chromatography (a separation technique used in drug development and drug production). The company’s mission is to contribute to better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.

Press release as pdf

Last updated:
October 17, 2019

Nanologica

Nanologica combines unique know-how in the field of materials technology with a genuine interest in solving real problems in life science.

Click here to read more about us!
Get in touch with us!
Visit us

Forskargatan 20G
SE-151 36 Södertälje, Sweden

Send us mail

The agreement between Nanologica and AstraZeneca for the evaluation of Nanologica’s pending patented technology applied to AstraZeneca materials has been extended.

The evaluation of the NLAB Silica™ drug delivery platform started at the beginning of 2019. It has now been decided to prolong and expand this collaboration project. The extension of the project is regulated under the same feasibility agreement as signed in January 2019. This extension will further evaluate Nanologica’s platform for the purpose of improving the formulation of an API.

” We are very positive about the extension of the project and are happy to keep working together with AstraZeneca”, says Nanologica’s CEO Andreas Bhagwani.

For further information, please contact:

Andreas Bhagwani, CEO of Nanologica
phone: +46 70 316 17 02 or e-mail: andreas.bhagwani@nanologica.com

About Nanologica AB (publ)
Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size and type of porosity of silica particles. This knowledge is applied within drug delivery and chromatography (a separation technique used in drug development and drug production). The company’s mission is to contribute to better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.

Press release as pdf

Last updated:
October 17, 2019

Nanologica

Nanologica combines unique know-how in the field of materials technology with a genuine interest in solving real problems in life science.

Click here to read more about us!
Get in touch with us!
Visit us

Forskargatan 20G
SE-151 36 Södertälje, Sweden

Send us mail